SpringWorks Therapeutics (SWTX) Stock Forecast, Price Target & Predictions
SWTX Stock Forecast
SpringWorks Therapeutics stock forecast is as follows: an average price target of $67.33 (represents a 117.61% upside from SWTX’s last price of $30.94) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SWTX Price Target
SWTX Analyst Ratings
SpringWorks Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 08, 2024 | Robert Burns | H.C. Wainwright | $76.00 | $33.93 | 123.99% | 145.64% |
Aug 09, 2022 | - | H.C. Wainwright | $94.00 | $39.66 | 137.01% | 203.81% |
May 27, 2022 | - | Wedbush | $50.00 | $18.72 | 167.09% | 61.60% |
May 24, 2022 | - | Goldman Sachs | $76.00 | $32.74 | 132.13% | 145.64% |
SpringWorks Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 1 | 1 |
Avg Price Target | - | $76.00 | $76.00 |
Last Closing Price | $30.94 | $30.94 | $30.94 |
Upside/Downside | -100.00% | 145.64% | 145.64% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 18, 2022 | H.C. Wainwright | Buy | Buy | Hold |
May 27, 2022 | Wedbush | Outperform | Outperform | Hold |
May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
SpringWorks Therapeutics Financial Forecast
SpringWorks Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $5.45M | - | - | $35.00M |
Avg Forecast | $128.90M | $109.34M | $91.23M | $78.04M | $66.44M | $55.14M | $34.42M | $12.07M | $860.19K | $3.82M | $180.00 | $21.00M |
High Forecast | $128.90M | $109.34M | $91.23M | $78.04M | $66.44M | $59.33M | $34.42M | $12.07M | $1.57M | $4.59M | $216.00 | $21.00M |
Low Forecast | $128.90M | $109.34M | $91.23M | $78.04M | $66.44M | $47.74M | $34.42M | $12.07M | $498.36K | $3.06M | $144.00 | $21.00M |
# Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
Surprise % | - | - | - | - | - | - | - | - | 6.33% | - | - | 1.67% |
SpringWorks Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
EBITDA | - | - | - | - | - | - | - | - | $-97.92M | $-61.36M | $-29.68M | $11.38M |
Avg Forecast | $-25.78M | $-21.87M | $-18.25M | $-15.61M | $-13.29M | $-11.03M | $-6.88M | $-2.41M | $-172.04K | $-47.26B | $-23.25M | $-4.20M |
High Forecast | $-25.78M | $-21.87M | $-18.25M | $-15.61M | $-13.29M | $-9.55M | $-6.88M | $-2.41M | $-99.67K | $-37.81B | $-18.60M | $-4.20M |
Low Forecast | $-25.78M | $-21.87M | $-18.25M | $-15.61M | $-13.29M | $-11.87M | $-6.88M | $-2.41M | $-314.04K | $-56.71B | $-27.90M | $-4.20M |
Surprise % | - | - | - | - | - | - | - | - | 569.21% | 0.00% | 1.28% | -2.71% |
SpringWorks Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
Net Income | - | - | - | - | - | - | - | - | $-94.32M | $-62.13M | $-29.79M | $11.27M |
Avg Forecast | $-11.15M | $-25.65M | $-37.36M | $-44.53M | $-50.23M | $-55.86M | $-82.73M | $-86.86M | $-91.66M | $-47.26B | $-23.36M | $-6.18M |
High Forecast | $-11.15M | $-25.65M | $-37.36M | $-44.53M | $-50.23M | $-44.10M | $-82.73M | $-86.86M | $-87.26M | $-37.81B | $-18.69M | $-6.18M |
Low Forecast | $-11.15M | $-25.65M | $-37.36M | $-44.53M | $-50.23M | $-69.83M | $-82.73M | $-86.86M | $-98.26M | $-56.71B | $-28.03M | $-6.18M |
Surprise % | - | - | - | - | - | - | - | - | 1.03% | 0.00% | 1.28% | -1.82% |
SpringWorks Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
SG&A | - | - | - | - | - | - | - | - | $59.84M | $27.37M | $12.38M | $8.52M |
Avg Forecast | $1.57B | $1.33B | $1.11B | $952.07M | $810.55M | $672.68M | $419.89M | $147.23M | $10.49M | $46.65M | $2.19K | $256.19M |
High Forecast | $1.57B | $1.33B | $1.11B | $952.07M | $810.55M | $723.81M | $419.89M | $147.24M | $19.16M | $55.98M | $2.63K | $256.19M |
Low Forecast | $1.57B | $1.33B | $1.11B | $952.07M | $810.55M | $582.46M | $419.89M | $147.23M | $6.08M | $37.32M | $1.76K | $256.19M |
Surprise % | - | - | - | - | - | - | - | - | 5.70% | 0.59% | 5640.55% | 0.03% |
SpringWorks Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 2 | 4 | 17 | 17 | 10 |
EPS | - | - | - | - | - | - | - | - | - | $-1.27 | $-0.62 | $0.26 |
Avg Forecast | $-0.15 | $-0.35 | $-0.50 | $-0.60 | $-0.68 | $-0.75 | $-1.12 | $-1.17 | $-1.24 | $-1.02 | $-0.51 | $-0.08 |
High Forecast | $-0.15 | $-0.35 | $-0.50 | $-0.60 | $-0.68 | $-0.59 | $-1.12 | $-1.17 | $-1.18 | $-1.02 | $-0.51 | $-0.08 |
Low Forecast | $-0.15 | $-0.35 | $-0.50 | $-0.60 | $-0.68 | $-0.94 | $-1.12 | $-1.17 | $-1.33 | $-1.02 | $-0.51 | $-0.08 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.24% | 1.22% | -3.12% |
SpringWorks Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
PASG | Passage Bio | $0.60 | $6.00 | 900.00% | Buy |
BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
ARVN | Arvinas | $26.80 | $71.82 | 167.99% | Buy |
APLS | Apellis Pharmaceuticals | $28.56 | $76.13 | 166.56% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
SWTX | SpringWorks Therapeutics | $30.94 | $67.33 | 117.61% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
RNA | Avidity Biosciences | $44.82 | $54.50 | 21.60% | Buy |
BPMC | Blueprint Medicines | $91.88 | $109.71 | 19.41% | Buy |
KYMR | Kymera Therapeutics | $47.07 | $51.50 | 9.41% | Buy |
RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
AMLX | Amylyx Pharmaceuticals | $5.70 | $5.33 | -6.49% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
SWTX Forecast FAQ
Is SpringWorks Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, SpringWorks Therapeutics (SWTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of SWTX's total ratings.
What is SWTX's price target?
SpringWorks Therapeutics (SWTX) average price target is $67.33 with a range of $50 to $76, implying a 117.61% from its last price of $30.94. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will SpringWorks Therapeutics stock go up soon?
According to Wall Street analysts' prediction for SWTX stock, the company can go up by 117.61% (from the last price of $30.94 to the average price target of $67.33), up by 145.64% based on the highest stock price target, and up by 61.60% based on the lowest stock price target.
Can SpringWorks Therapeutics stock reach $50?
SWTX's average twelve months analyst stock price target of $67.33 supports the claim that SpringWorks Therapeutics can reach $50 in the near future.
What are SpringWorks Therapeutics's analysts' financial forecasts?
SpringWorks Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $168.07M (high $172.26M, low $160.67M), average EBITDA is $-33.613M (high $-32.134M, low $-34.451M), average net income is $-276M (high $-264M, low $-290M), average SG&A $2.05B (high $2.1B, low $1.96B), and average EPS is $-3.719 (high $-3.561, low $-3.908). SWTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $407.5M (high $407.5M, low $407.5M), average EBITDA is $-81.5M (high $-81.5M, low $-81.5M), average net income is $-119M (high $-119M, low $-119M), average SG&A $4.97B (high $4.97B, low $4.97B), and average EPS is $-1.601 (high $-1.601, low $-1.601).
Did the SWTX's actual financial results beat the analysts' financial forecasts?
Based on SpringWorks Therapeutics's last annual report (Dec 2023), the company's revenue was $5.45M, beating the average analysts forecast of $860.19K by 533.23%. Apple's EBITDA was $-343M, beating the average prediction of $-172K by 199283.27%. The company's net income was $-325M, beating the average estimation of $-91.664M by 254.67%. Apple's SG&A was $197.55M, beating the average forecast of $10.49M by 1782.50%. Lastly, the company's EPS was $-0.0052, missing the average prediction of $-1.237 by -99.58%. In terms of the last quarterly report (Dec 2023), SpringWorks Therapeutics's revenue was $5.45M, beating the average analysts' forecast of $860.19K by 533.23%. The company's EBITDA was $-97.925M, beating the average prediction of $-172K by 56820.89%. SpringWorks Therapeutics's net income was $-94.322M, beating the average estimation of $-91.664M by 2.90%. The company's SG&A was $59.84M, beating the average forecast of $10.49M by 470.19%. Lastly, the company's EPS was $0, missing the average prediction of $-1.237 by -100.00%